ESMO: Bristol-Myers, Roche, AstraZeneca, GSK, Merck jostle for spotlight

September 29, 2014 11:16 AM

3 0

Over the weekend oncology investigators from all around the world gathered in Madrid at the European Society for Medical Oncology (ESMO) 2014 Congress to review the latest advances--and setbacks--in the fast-moving field of cancer drug research. As usual, the big companies dominated the discussions, as rival oncology groups touted new data as they tried to position competing therapies in the global scramble to develop new and better cancer drugs, now one of the hottest fields in R&D.

Bristol-Myers Squibb ($BMY) offered up a premier batch of late-stage evidence of the potential of its anti-PD-1 checkpoint inhibitor nivolumab (Opdivo). At the interim analysis the drug was credited with a 32% objective response rate among patients with advanced melanoma while the chemo control grou...

Read more

To category page